Immuneering Corp Class A (IMRX) Stock Price

6.11 ▲ +0.22 (+3.74%)
Open: 5.87 Vol: 10.21K Day's range: 5.80 - 6.135 Apr 23, 15:59 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
IMRX Technical Analysis
5 mins 30 mins Hourly Daily Weekly
BUY BUY BUY BUY BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 6.09▲ 6.09▲ 6.09▲ 5.73▲ 5.52▲
MA10 6.09▲ 6.07▲ 5.98▲ 5.66▲ 5.30▲
MA20 6.09▲ 5.94▲ 5.80▲ 5.47▲ 5.36▲
MA50 6.08▲ 5.70▲ 5.63▲ 5.26▲ 5.11▲
MA100 5.98▲ 5.62▲ 5.57▲ 5.48▲ 3.41▲
MA200 5.81▲ 5.55▲ 5.31▲ 5.63▲ 5.26▲
  5 mins 30 mins Hourly Daily Weekly
MACD -0.001▼ 0.005▲ 0.037▲ 0.047▲ 0.037▲
RSI 58.150▲ 67.312▲ 68.602▲ 64.897▲ 57.023▲
STOCH 42.482     80.953▲ 88.860▲ 67.535     66.788    
WILL %R -26.667     -7.463▲ -4.065▲ -2.618▲ -1.401▲
CCI 158.621▲ 69.180     94.839     264.453▲ 199.129▲
Latest Filters Detected On IMRX
▲ BREAK $IMRX Price Breaks 60 Days High Set Alert
▲ BREAK $IMRX Price Breaks 30 Days High Set Alert
▲ BREAK $IMRX Price Breaks 20 Days High Set Alert
▲ BREAK $IMRX Price Breaks 10 Days High Set Alert
Immuneering Corp Class A News
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
Tuesday, April 21, 2026 02:46 PM
New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - - The ASCO presentation ...
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic ...
Monday, April 20, 2026 08:28 AM
Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors ...
Immuneering Corp.
Sunday, April 19, 2026 11:27 AM
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that ...
IMRX historical stock data
date open high low close volume
23/04/26 5.87 6.135 5.80 6.11 888,084
22/04/26 5.59 5.915 5.51 5.89 894,117
21/04/26 5.52 5.715 5.47 5.55 722,627
20/04/26 5.635 5.68 5.2775 5.53 709,427
17/04/26 5.73 5.85 5.5001 5.56 795,614
16/04/26 5.75 5.755 5.43 5.57 1,044,578
15/04/26 5.44 5.75 5.2513 5.75 893,606
14/04/26 5.75 5.83 5.39 5.41 994,042
13/04/26 5.52 5.845 5.4803 5.70 759,020
10/04/26 5.68 5.77 5.45 5.52 573,626
Quote Details
52wk Low:1.10
52wk High:10.08
Vol:10.21K
Avg Vol(3m):17.2M
1Y Chng:+435.96%
1M Chng:+12.11%
Add to Watch List
More Information
Index US Composite
Market Cap. 359.07M